mRNA cancer vaccines could be in greater focus after Moderna, Merck candidate shines

Dec. 13, 2022 2:04 PM ETModerna, Inc. (MRNA), MRKAMZN, GSK, NVS, PFE, LLY, SNY, AGEN, GOVX, ANIX, TAK, VBIV, IBRX, AUTL, GRTS, BNTX, CVAC, DTCFFBy: Ravikash, SA News Editor120 Comments

mRNA Technology - Messenger RNA - Two Strands of mRNA on Abstract Technology Background


Moderna (NASDAQ:MRNA) stock soared on Tuesday after the first show of impressive efficacy results for a personalized mRNA cancer vaccine in a randomized clinical trial. Shares are up 24% in afternoon trading.

Moderna (MRNA), which rose to fame and

Recommended For You

Comments (120)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.